The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
The purpose of this study was to examine the prognostic capability of baseline neutrophil-to-lymphocyte-ratio (NLR) and NLR-change under Abiraterone in metastatic castration-resistant prostate cancer patients. The impact of baseline NLR and change after eight weeks of treatment on progression-free s...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/18/2/380 |
id |
doaj-bfff68dcfe024b168ab6e3187c4c12e8 |
---|---|
record_format |
Article |
spelling |
doaj-bfff68dcfe024b168ab6e3187c4c12e82020-11-24T21:45:51ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-02-0118238010.3390/ijms18020380ijms18020380The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with AbirateroneMartin Boegemann0Katrin Schlack1Stefan Thomes2Julie Steinestel3Kambiz Rahbar4Axel Semjonow5Andres Jan Schrader6Martin Aringer7Laura-Maria Krabbe8Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyDepartment of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyDepartment of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyDepartment of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyDepartment of Nuclear Medicine, Muenster University Medical Center, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyDepartment of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyDepartment of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyDepartment of Rheumatology, Dresden University Medical Center, Fetscherstraße 74, D-01307 Dresden, GermanyDepartment of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, GermanyThe purpose of this study was to examine the prognostic capability of baseline neutrophil-to-lymphocyte-ratio (NLR) and NLR-change under Abiraterone in metastatic castration-resistant prostate cancer patients. The impact of baseline NLR and change after eight weeks of treatment on progression-free survival (PFS) and overall survival (OS) was analyzed using Kaplan-Meier-estimates and Cox-regression. 79 men with baseline NLR <5 and 17 with NLR >5 were analyzed. In baseline analysis of PFS NLR >5 was associated with non-significantly shorter median PFS (five versus 10 months) (HR: 1.6 (95%CI:0.9–2.8); p = 0.11). After multivariate adjustment (MVA), ECOG > 0–1, baseline LDH>upper limit of normal (UNL) and presence of visceral metastases were independent prognosticators. For OS, NLR >5 was associated with shorter survival (seven versus 19 months) (HR: 2.3 (95%CI:1.3–4.0); p < 0.01). In MVA, ECOG > 0–1 and baseline LDH > UNL remained independent prognosticators. After 8 weeks of Abiraterone NLR-change to <5 prognosticated worse PFS (five versus 12 months) (HR: 4.1 (95%CI:1.1–15.8); p = 0.04). MVA showed a trend towards worse PFS for NLR-change to <5 (p = 0.11). NLR-change to <5 led to non-significant shorter median OS (seven versus 16 months) (HR: 2.3 (95%CI:0.7–7.1); p = 0.15). MVA showed non-significant difference for OS. We concluded baseline NLR <5 is associated with improved survival. In contrast, in patients with baseline NLR >5, NLR-change to <5 after eight weeks of Abiraterone was associated with worse survival and should be interpreted carefully.http://www.mdpi.com/1422-0067/18/2/380neutrophil-to-lymphocyte ratiocastration-resistant prostate cancerprognostic biomarkertreatment responseabiraterone |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Martin Boegemann Katrin Schlack Stefan Thomes Julie Steinestel Kambiz Rahbar Axel Semjonow Andres Jan Schrader Martin Aringer Laura-Maria Krabbe |
spellingShingle |
Martin Boegemann Katrin Schlack Stefan Thomes Julie Steinestel Kambiz Rahbar Axel Semjonow Andres Jan Schrader Martin Aringer Laura-Maria Krabbe The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone International Journal of Molecular Sciences neutrophil-to-lymphocyte ratio castration-resistant prostate cancer prognostic biomarker treatment response abiraterone |
author_facet |
Martin Boegemann Katrin Schlack Stefan Thomes Julie Steinestel Kambiz Rahbar Axel Semjonow Andres Jan Schrader Martin Aringer Laura-Maria Krabbe |
author_sort |
Martin Boegemann |
title |
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone |
title_short |
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone |
title_full |
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone |
title_fullStr |
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone |
title_full_unstemmed |
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone |
title_sort |
role of the neutrophil to lymphocyte ratio for survival outcomes in patients with metastatic castration-resistant prostate cancer treated with abiraterone |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2017-02-01 |
description |
The purpose of this study was to examine the prognostic capability of baseline neutrophil-to-lymphocyte-ratio (NLR) and NLR-change under Abiraterone in metastatic castration-resistant prostate cancer patients. The impact of baseline NLR and change after eight weeks of treatment on progression-free survival (PFS) and overall survival (OS) was analyzed using Kaplan-Meier-estimates and Cox-regression. 79 men with baseline NLR <5 and 17 with NLR >5 were analyzed. In baseline analysis of PFS NLR >5 was associated with non-significantly shorter median PFS (five versus 10 months) (HR: 1.6 (95%CI:0.9–2.8); p = 0.11). After multivariate adjustment (MVA), ECOG > 0–1, baseline LDH>upper limit of normal (UNL) and presence of visceral metastases were independent prognosticators. For OS, NLR >5 was associated with shorter survival (seven versus 19 months) (HR: 2.3 (95%CI:1.3–4.0); p < 0.01). In MVA, ECOG > 0–1 and baseline LDH > UNL remained independent prognosticators. After 8 weeks of Abiraterone NLR-change to <5 prognosticated worse PFS (five versus 12 months) (HR: 4.1 (95%CI:1.1–15.8); p = 0.04). MVA showed a trend towards worse PFS for NLR-change to <5 (p = 0.11). NLR-change to <5 led to non-significant shorter median OS (seven versus 16 months) (HR: 2.3 (95%CI:0.7–7.1); p = 0.15). MVA showed non-significant difference for OS. We concluded baseline NLR <5 is associated with improved survival. In contrast, in patients with baseline NLR >5, NLR-change to <5 after eight weeks of Abiraterone was associated with worse survival and should be interpreted carefully. |
topic |
neutrophil-to-lymphocyte ratio castration-resistant prostate cancer prognostic biomarker treatment response abiraterone |
url |
http://www.mdpi.com/1422-0067/18/2/380 |
work_keys_str_mv |
AT martinboegemann theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT katrinschlack theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT stefanthomes theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT juliesteinestel theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT kambizrahbar theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT axelsemjonow theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT andresjanschrader theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT martinaringer theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT lauramariakrabbe theroleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT martinboegemann roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT katrinschlack roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT stefanthomes roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT juliesteinestel roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT kambizrahbar roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT axelsemjonow roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT andresjanschrader roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT martinaringer roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone AT lauramariakrabbe roleoftheneutrophiltolymphocyteratioforsurvivaloutcomesinpatientswithmetastaticcastrationresistantprostatecancertreatedwithabiraterone |
_version_ |
1725903854659174400 |